{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:45:04Z","timestamp":1787942704727,"version":"build-2784847793"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"colorectal cancer prevention and control"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02230-x","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T15:06:05Z","timestamp":1769699165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting glucocorticoid receptor to enhance immunotherapy response in triple negative breast cancer"],"prefix":"10.1186","volume":"28","author":[{"given":"Lei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengchun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxue","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"issue":"2","key":"2230_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19(2):91\u2013113.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2230_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12032-023-02257-6","volume":"41","author":"M Capuozzo","year":"2023","unstructured":"Capuozzo M, Celotto V, Santorsola M, Fabozzi A, Landi L, Ferrara F, Borzacchiello A, Granata V, Sabbatino F, Savarese G, Cascella M, Perri F, Ottaiano A. Emerging treatment approaches for triple-negative breast cancer. Med Oncol. 2023;41(1):5.","journal-title":"Med Oncol"},{"issue":"1","key":"2230_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","volume":"21","author":"KC Ohaegbulam","year":"2015","unstructured":"Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24\u201333.","journal-title":"Trends Mol Med"},{"issue":"11","key":"2230_CR4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651\u201368.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2230_CR5","doi-asserted-by":"publisher","first-page":"e000255","DOI":"10.1136\/esmoopen-2017-000255","volume":"2","author":"C Solinas","year":"2017","unstructured":"Solinas C, Gombos A, Latifyan S, Piccart-Gebhart M, Kok M, Buisseret L. Targeting immune checkpoints in breast cancer: an update of early results. ESMO Open. 2017;2(5):e000255.","journal-title":"ESMO Open"},{"issue":"4","key":"2230_CR6","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1172\/JCI96313","volume":"129","author":"T Gruosso","year":"2019","unstructured":"Gruosso T, Gigoux M, Manem VSK, Bertos N, Zuo D, Perlitch I, Saleh SMI, Zhao H, Souleimanova M, Johnson RM, Monette A, Ramos VM, Hallett MT, Stagg J, Lapointe R, Omeroglu A, Meterissian S, Buisseret L, Van den Eynden G, Salgado R, Guiot MC, Haibe-Kains B, Park M. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Invest. 2019;129(4):1785\u2013800.","journal-title":"J Clin Invest"},{"issue":"1","key":"2230_CR7","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1038\/s41467-021-25962-0","volume":"12","author":"D Hammerl","year":"2021","unstructured":"Hammerl D, Martens JWM, Timmermans M, Smid M, Trapman-Jansen AM, Foekens R, Isaeva OI, Voorwerk L, Balcioglu HE, Wijers R, Nederlof I, Salgado R, Horlings H, Kok M, Debets R. Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nat Commun. 2021;12(1):5668.","journal-title":"Nat Commun"},{"key":"2230_CR8","doi-asserted-by":"publisher","unstructured":"Ren D, Hua Y, Yu B, Ye X, He Z, Li C, Wang J, Mo Y, Wei X, Chen Y, Zhou Y, Liao Q, Wang H, Xiang B, Zhou M, Li X, Li G, Li Y, Zeng Z, Xiong W. Predictive biomarkers and mechanisms underlying resistance to PD1\/PD-L1 blockade cancer immunotherapy. Mol Cancer. 2020;19(1):19. https:\/\/doi.org\/10.1186\/s12943-020-1144-6. Erratum in: Mol Cancer. 2020;19(1):31.","DOI":"10.1186\/s12943-020-1144-6"},{"issue":"1","key":"2230_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2023.12.012","volume":"42","author":"SL Shiao","year":"2024","unstructured":"Shiao SL, Gouin KH 3rd, Ing N, Ho A, Basho R, Shah A, Mebane RH, Zitser D, Martinez A, Mevises NY, Ben-Cheikh B, Henson R, Mita M, McAndrew P, Karlan S, Giuliano A, Chung A, Amersi F, Dang C, Richardson H, Shon W, Dadmanesh F, Burnison M, Mirhadi A, Zumsteg ZS, Choi R, Davis M, Lee J, Rollins D, Martin C, Khameneh NH, McArthur H, Knott SRV. Single-cell and Spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer. Cancer Cell. 2024;42(1):70\u2013e848.","journal-title":"Cancer Cell"},{"issue":"1","key":"2230_CR10","doi-asserted-by":"publisher","first-page":"8514","DOI":"10.1038\/s41467-024-52553-6","volume":"15","author":"W Zheng","year":"2024","unstructured":"Zheng W, Marini W, Murakami K, Sotov V, Butler M, Gorrini C, Ohashi PS, Reedijk M. Caspase-1-dependent spatiality in triple-negative breast cancer and response to immunotherapy. Nat Commun. 2024;15(1):8514.","journal-title":"Nat Commun"},{"issue":"3","key":"2230_CR11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1158\/0008-5472.CAN-20-1818","volume":"81","author":"P Falvo","year":"2021","unstructured":"Falvo P, Orecchioni S, Hillje R, Raveane A, Mancuso P, Camisaschi C, Luzi L, Pelicci P, Bertolini F. Cyclophosphamide and Vinorelbine activate Stem-Like CD8\u2009+\u2009T cells and improve Anti-PD-1 efficacy in Triple-Negative breast cancer. Cancer Res. 2021;81(3):685\u201397.","journal-title":"Cancer Res"},{"issue":"8","key":"2230_CR12","doi-asserted-by":"publisher","first-page":"e2114851119","DOI":"10.1073\/pnas.2114851119","volume":"119","author":"R Zhang","year":"2022","unstructured":"Zhang R, Yang Y, Dong W, Lin M, He J, Zhang X, Tian T, Yang Y, Chen K, Lei QY, Zhang S, Xu Y, Lv L. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1. Proc Natl Acad Sci U S A. 2022;119(8):e2114851119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2230_CR13","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1158\/2159-8290.CD-23-0519","volume":"14","author":"BC Taylor","year":"2024","unstructured":"Taylor BC, Sun X, Gonzalez-Ericsson PI, Sanchez V, Sanders ME, Wescott EC, Opalenik SR, Hanna A, Chou ST, Van Kaer L, Gomez H, Isaacs C, Ballinger TJ, Santa-Maria CA, Shah PD, Dees EC, Lehmann BD, Abramson VG, Pietenpol JA, Balko JM. NKG2A is a therapeutic vulnerability in immunotherapy resistant MHC-I heterogeneous Triple-Negative breast cancer. Cancer Discov. 2024;14(2):290\u2013307.","journal-title":"Cancer Discov"},{"issue":"13","key":"2230_CR14","doi-asserted-by":"publisher","first-page":"9413","DOI":"10.1021\/acsnano.3c11023","volume":"18","author":"X Xu","year":"2024","unstructured":"Xu X, Zheng J, Liang N, Zhang X, Shabiti S, Wang Z, Yu S, Pan ZY, Li W, Cai L. Bioorthogonal\/Ultrasound activated oncolytic pyroptosis amplifies in situ tumor vaccination for boosting antitumor immunity. ACS Nano. 2024;18(13):9413\u201330.","journal-title":"ACS Nano"},{"key":"2230_CR15","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jconrel.2024.07.074","volume":"375","author":"HR Kim","year":"2024","unstructured":"Kim HR, Park SJ, Cho YS, Ko YG, Kim SY, Byun Y. Synergistic anticancer immunity in metastatic triple-negative breast cancer through an in situ amplifying Peptide-Drug conjugate. J Control Release. 2024;375:681\u201397.","journal-title":"J Control Release"},{"issue":"13","key":"2230_CR16","doi-asserted-by":"publisher","first-page":"e2419418","DOI":"10.1002\/adma.202419418","volume":"37","author":"S Deng","year":"2025","unstructured":"Deng S, Hu L, Chen G, Ye J, Xiao Z, Guan T, Guo S, Xia W, Cheng D, Wan X, Cheng K, Ou C. A PD-L1 siRNA-Loaded Boron nanoparticle for targeted cancer radiotherapy and immunotherapy. Adv Mater. 2025;37(13):e2419418.","journal-title":"Adv Mater"},{"issue":"4","key":"2230_CR17","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s43018-025-00930-5","volume":"6","author":"Y Tao","year":"2025","unstructured":"Tao Y, Tian C, Qi S, Jia Z, Xu Z, Meng J, Xu G, Hu H, Wang X, Zhang T, You H, Lan X, Lin X, Yu G, Zhou H, Liu J, Zheng H. Targeting both death and Paracaspase domains of MALT1 with antisense oligonucleotides overcomes resistance to immune-checkpoint inhibitors. Nat Cancer. 2025;6(4):702\u201317.","journal-title":"Nat Cancer"},{"issue":"7","key":"2230_CR18","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1053\/j.gastro.2023.02.043","volume":"164","author":"Y Saito","year":"2023","unstructured":"Saito Y, Yin D, Kubota N, Wang X, Filliol A, Remotti H, Nair A, Fazlollahi L, Hoshida Y, Tabas I, Wangensteen KJ, Schwabe RF. A therapeutically targetable TAZ-TEAD2 pathway drives the growth of hepatocellular carcinoma via ANLN and KIF23. Gastroenterology. 2023;164(7):1279\u201392.","journal-title":"Gastroenterology"},{"key":"2230_CR19","doi-asserted-by":"publisher","first-page":"122723","DOI":"10.1016\/j.biomaterials.2024.122723","volume":"312","author":"L Wu","year":"2025","unstructured":"Wu L, Pi W, Huang X, Yang L, Zhang X, Lu J, Yao S, Lin X, Tan X, Wang Z, Wang P. Orchestrated metal-coordinated carrier-free Celastrol hydrogel intensifies T cell activation and regulates response to immune checkpoint Blockade for synergistic chemo-immunotherapy. Biomaterials. 2025;312:122723.","journal-title":"Biomaterials"},{"issue":"1","key":"2230_CR20","first-page":"55","volume":"21","author":"RM Sapolsky","year":"2000","unstructured":"Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev. 2000;21(1):55\u201389.","journal-title":"Endocr Rev"},{"issue":"7749","key":"2230_CR21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41586-019-1019-4","volume":"567","author":"MMS Obradovi\u0107","year":"2019","unstructured":"Obradovi\u0107 MMS, Hamelin B, Manevski N, Couto JP, Sethi A, Coissieux MM, M\u00fcnst S, Okamoto R, Kohler H, Schmidt A, Bentires-Alj M. Glucocorticoids promote breast cancer metastasis. Nature. 2019;567(7749):540\u20134.","journal-title":"Nature"},{"issue":"14","key":"2230_CR22","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1158\/1078-0432.CCR-17-2793","volume":"24","author":"DC West","year":"2018","unstructured":"West DC, Kocherginsky M, Tonsing-Carter EY, Dolcen DN, Hosfield DJ, Lastra RR, Sinnwell JP, Thompson KJ, Bowie KR, Harkless RV, Skor MN, Pierce CF, Styke SC, Kim CR, de Wet L, Greene GL, Boughey JC, Goetz MP, Kalari KR, Wang L, Fleming GF, Gy\u00f6rffy B, Conzen SD. Discovery of a glucocorticoid receptor (GR) activity signature using selective GR antagonism in ER-Negative breast cancer. Clin Cancer Res. 2018;24(14):3433\u201346.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"2230_CR23","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.3390\/cells11142126","volume":"11","author":"L Rocamora-Reverte","year":"2022","unstructured":"Rocamora-Reverte L, Villunger A, Wiegers GJ. Cell-Specific immune regulation by glucocorticoids in murine models of infection and inflammation. Cells. 2022;11(14):2126.","journal-title":"Cells"},{"issue":"3","key":"2230_CR24","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.immuni.2020.08.005","volume":"53","author":"N Acharya","year":"2020","unstructured":"Acharya N, Madi A, Zhang H, Klapholz M, Escobar G, Dulberg S, Christian E, Ferreira M, Dixon KO, Fell G, Tooley K, Mangani D, Xia J, Singer M, Bosenberg M, Neuberg D, Rozenblatt-Rosen O, Regev A, Kuchroo VK, Anderson AC. Endogenous glucocorticoid signaling regulates CD8\u2009+\u2009T cell differentiation and development of dysfunction in the tumor microenvironment. Immunity. 2020;53(3):658\u2013e6716.","journal-title":"Immunity"},{"issue":"9","key":"2230_CR25","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/s41591-019-0566-4","volume":"25","author":"H Yang","year":"2019","unstructured":"Yang H, Xia L, Chen J, Zhang S, Martin V, Li Q, Lin S, Chen J, Calmette J, Lu M, Fu L, Yang J, Pan Z, Yu K, He J, Morand E, Schlecht-Louf G, Krzysiek R, Zitvogel L, Kang B, Zhang Z, Leader A, Zhou P, Lanfumey L, Shi M, Kroemer G, Ma Y. Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity. Nat Med. 2019;25(9):1428\u201341.","journal-title":"Nat Med"},{"issue":"3","key":"2230_CR26","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2024.01.013","volume":"42","author":"XY He","year":"2024","unstructured":"He XY, Gao Y, Ng D, Michalopoulou E, George S, Adrover JM, Sun L, Albrengues J, Da\u00dfler-Plenker J, Han X, Wan L, Wu XS, Shui LS, Huang YH, Liu B, Su C, Spector DL, Vakoc CR, Van Aelst L, Egeblad M. Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment. Cancer Cell. 2024;42(3):474\u2013e48612.","journal-title":"Cancer Cell"},{"issue":"4","key":"2230_CR27","first-page":"867","volume":"60","author":"TJ Moran","year":"2000","unstructured":"Moran TJ, Gray S, Mikosz CA, Conzen SD. The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res. 2000;60(4):867\u201372.","journal-title":"Cancer Res"},{"issue":"4","key":"2230_CR28","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s10555-022-10047-1","volume":"41","author":"H Butz","year":"2022","unstructured":"Butz H, Pat\u00f3cs A. Mechanisms behind context-dependent role of glucocorticoids in breast cancer progression. Cancer Metastasis Rev. 2022;41(4):803\u201332.","journal-title":"Cancer Metastasis Rev"},{"issue":"12","key":"2230_CR29","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1200\/JCO.2010.34.0331","volume":"30","author":"CJ Hoffman","year":"2012","unstructured":"Hoffman CJ, Ersser SJ, Hopkinson JB, Nicholls PG, Harrington JE, Thomas PW. Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to III breast cancer: a randomized, controlled trial. J Clin Oncol. 2012;30(12):1335\u201342.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2230_CR30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1210\/endocr\/bqad126","volume":"164","author":"L Hilakivi-Clarke","year":"2023","unstructured":"Hilakivi-Clarke L, de Oliveira Andrade F. Social isolation and breast cancer. Endocrinology. 2023;164(10):126.","journal-title":"Endocrinology"},{"issue":"Suppl 1","key":"2230_CR31","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1093\/gerona\/glac053","volume":"77","author":"AH Shadyab","year":"2022","unstructured":"Shadyab AH, Larson JC, Rapp SR, Shumaker SA, Kroenke CH, Meliker J, Saquib N, Ikramuddin F, Michael YL, Goveas JS, Garcia L, Wactawski-Wende J, Luo J, Hayden KM, Chen JC, Weitlauf J, Baker LD. Association of global cognitive function with psychological distress and adherence to public health recommendations during the coronavirus disease 2019 pandemic: the women\u2019s health initiative. J Gerontol Biol Sci Med Sci. 2022;77(Suppl 1):S42\u201350.","journal-title":"J Gerontol Biol Sci Med Sci"},{"issue":"8","key":"2230_CR32","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.2337\/dc19-2065","volume":"43","author":"J Miao Jonasson","year":"2020","unstructured":"Miao Jonasson J, Hendryx M, Shadyab AH, Kelley E, Johnson KC, Kroenke CH, Garcia L, Lawesson S, Santosa A, Sealy-Jefferson S, Lin X, Cene CW, Liu S, Valdiviezo C, Luo J. Social Support, social network Size, social Strain, stressful life Events, and coronary heart disease in women with type 2 diabetes: A cohort study based on the women\u2019s health initiative. Diabetes Care. 2020;43(8):1759\u201366.","journal-title":"Diabetes Care"},{"issue":"4","key":"2230_CR33","doi-asserted-by":"publisher","first-page":"e005284","DOI":"10.1161\/CIRCOUTCOMES.118.005284","volume":"12","author":"AS Felix","year":"2019","unstructured":"Felix AS, Lehman A, Nolan TS, Sealy-Jefferson S, Breathett K, Hood DB, Addison D, Anderson CM, Cen\u00e9 CW, Warren BJ, Jackson RD, Williams KP. Stress, Resilience, and cardiovascular disease risk among black women. Circ Cardiovasc Qual Outcomes. 2019;12(4):e005284.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"3","key":"2230_CR34","doi-asserted-by":"publisher","first-page":"e000687","DOI":"10.1161\/JAHA.113.000687","volume":"3","author":"KN Kershaw","year":"2014","unstructured":"Kershaw KN, Brenes GA, Charles LE, Coday M, Daviglus ML, Denburg NL, Kroenke CH, Safford MM, Savla T, Tindle HA, Tinker LF, Van Horn L. Associations of stressful life events and social strain with incident cardiovascular disease in the women\u2019s health initiative. J Am Heart Assoc. 2014;3(3):e000687.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2230_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.canlet.2008.10.028","volume":"276","author":"M Liang","year":"2009","unstructured":"Liang M, Yang H, Fu J. Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms. Cancer Lett. 2009;276(1):47\u201352.","journal-title":"Cancer Lett"},{"issue":"11","key":"2230_CR36","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.7150\/thno.74989","volume":"12","author":"B Wu","year":"2022","unstructured":"Wu B, Song M, Dong Q, Xiang G, Li J, Ma X, Wei F. UBR5 promotes tumor immune evasion through enhancing IFN-\u03b3-induced PDL1 transcription in triple negative breast cancer. Theranostics. 2022;12(11):5086\u2013102.","journal-title":"Theranostics"},{"issue":"8","key":"2230_CR37","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, Herbrich SM, Anandhan S, Islam S, Amit M, Anandappa G, Allison JP. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186(8):1652\u201369.","journal-title":"Cell"},{"key":"2230_CR38","doi-asserted-by":"publisher","first-page":"106988","DOI":"10.1016\/j.phrs.2023.106988","volume":"198","author":"MY Huang","year":"2023","unstructured":"Huang MY, Chen YC, Lyu WY, He XY, Ye ZH, Huang CY, He XL, Chen X, Chen X, Zhang B, Kai G, Zhang X, Li T, Huang M, Lu JJ. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8\u2009+\u2009T cells via increasing intratumoral CXCL10. Pharmacol Res. 2023;198:106988.","journal-title":"Pharmacol Res"},{"issue":"85","key":"2230_CR39","doi-asserted-by":"publisher","first-page":"eadd4817","DOI":"10.1126\/sciimmunol.add4817","volume":"8","author":"O Zimmermannova","year":"2023","unstructured":"Zimmermannova O, Ferreira AG, Ascic E, Velasco Santiago M, Kurochkin I, Hansen M, Met \u00d6, Caiado I, Shapiro IE, Michaux J, Humbert M, Soto-Cabrera D, Benonisson H, Silv\u00e9rio-Alves R, Gomez-Jimenez D, Bernardo C, Bauden M, Andersson R, H\u00f6glund M, Miharada K, Nakamura Y, Hugues S, Greiff L, Lindstedt M, Rosa FF, Pires CF, Bassani-Sternberg M, Svane IM, Pereira CF. Restoring tumor immunogenicity with dendritic cell reprogramming. Sci Immunol. 2023;8(85):eadd4817.","journal-title":"Sci Immunol"},{"issue":"4","key":"2230_CR40","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41388-023-02901-5","volume":"43","author":"A Eigentler","year":"2024","unstructured":"Eigentler A, Handle F, Schanung S, Degen A, Hackl H, Erb HHH, Fotakis G, Hoefer J, Ploner C, J\u00f6hrer K, Heidegger I, Pircher A, Klotz W, Herold M, Sch\u00e4fer G, Culig Z, Puhr M. Glucocorticoid treatment influences prostate cancer cell growth and the tumor microenvironment via altered glucocorticoid receptor signaling in prostate fibroblasts. Oncogene. 2024;43(4):235\u201347.","journal-title":"Oncogene"},{"issue":"4","key":"2230_CR41","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nri.2017.1","volume":"17","author":"DW Cain","year":"2017","unstructured":"Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17(4):233\u201347.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2230_CR42","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1158\/2159-8290.CD-20-0812","volume":"11","author":"SS Gu","year":"2021","unstructured":"Gu SS, Zhang W, Wang X, Jiang P, Traugh N, Li Z, Meyer C, Stewig B, Xie Y, Bu X, Manos MP, Font-Tello A, Gjini E, Lako A, Lim K, Conway J, Tewari AK, Zeng Z, Sahu AD, Tokheim C, Weirather JL, Fu J, Zhang Y, Kroger B, Liang JH, Cejas P, Freeman GJ, Rodig S, Long HW, Gewurz BE, Hodi FS, Brown M, Liu XS. Therapeutically increasing MHC-I expression potentiates immune checkpoint Blockade. Cancer Discov. 2021;11(6):1524\u201341.","journal-title":"Cancer Discov"},{"issue":"5","key":"2230_CR43","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-23-0700","volume":"14","author":"T Tani","year":"2024","unstructured":"Tani T, Mathsyaraja H, Campisi M, Li ZH, Haratani K, Fahey CG, Ota K, Mahadevan NR, Shi Y, Saito S, Mizuno K, Thai TC, Sasaki N, Homme M, Yusuf CFB, Kashishian A, Panchal J, Wang M, Wolf BJ, Barbie TU, Paweletz CP, Gokhale PC, Liu D, Uppaluri R, Kitajima S, Cain J, Barbie DA. TREX1 inactivation unleashes cancer cell STING-Interferon signaling and promotes antitumor immunity. Cancer Discov. 2024;14(5):752\u201365.","journal-title":"Cancer Discov"},{"issue":"1","key":"2230_CR44","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12943-024-02176-8","volume":"23","author":"M Jin","year":"2024","unstructured":"Jin M, Fang J, Peng J, Wang X, Xing P, Jia K, Hu J, Wang D, Ding Y, Wang X, Li W, Chen Z. PD-1\/PD-L1 immune checkpoint Blockade in breast cancer: research insights and sensitization strategies. Mol Cancer. 2024;23(1):266.","journal-title":"Mol Cancer"},{"issue":"1","key":"2230_CR45","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12943-024-02179-5","volume":"23","author":"J Wei","year":"2024","unstructured":"Wei J, Li W, Zhang P, Guo F, Liu M. Current trends in sensitizing immune checkpoint inhibitors for cancer treatment. Mol Cancer. 2024;23(1):279.","journal-title":"Mol Cancer"},{"issue":"6","key":"2230_CR46","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1056\/NEJM199308053290607","volume":"329","author":"IM Spitz","year":"1993","unstructured":"Spitz IM, Bardin CW. Mifepristone (RU 486)--a modulator of progestin and glucocorticoid action. N Engl J Med. 1993;329(6):404\u201312.","journal-title":"N Engl J Med"},{"issue":"5","key":"2230_CR47","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/cpt.3392","volume":"116","author":"JV Turner","year":"2024","unstructured":"Turner JV, Garratt D, Barwick A, McLindon LA, Spark MJ, Smith A. Congenital and fetal effects after mifepristone exposure and continuation of pregnancy: a systematic review. Clin Pharmacol Ther. 2024;116(5):1207\u201316.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2230_CR48","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1530\/EJE-07-0458","volume":"157","author":"S Johanssen","year":"2007","unstructured":"Johanssen S, Allolio B. Mifepristone (RU 486) in cushing\u2019s syndrome. Eur J Endocrinol. 2007;157(5):561\u20139.","journal-title":"Eur J Endocrinol"},{"key":"2230_CR49","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.canlet.2021.07.034","volume":"520","author":"O Lee","year":"2021","unstructured":"Lee O, Bosland MC, Wang M, Shidfar A, Hosseini O, Xuei X, Patel P, Schipma MJ, Helenowski I, Kim JJ, Clare SE, Khan SA. Selective progesterone receptor Blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes. Cancer Lett. 2021;520:255\u201366.","journal-title":"Cancer Lett"},{"issue":"5","key":"2230_CR50","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/0008-5472.CAN-20-1441","volume":"81","author":"GR Sequeira","year":"2021","unstructured":"Sequeira GR, Sahores A, Dalotto-Moreno T, Perrotta RM, Pataccini G, Vanzulli SI, Polo ML, Radisky DC, Sartorius CA, Novaro V, Lamb CA, Rabinovich GA, Salatino M, Lanari C. Enhanced antitumor immunity via endocrine therapy prevents mammary tumor relapse and increases immune checkpoint Blockade sensitivity. Cancer Res. 2021;81(5):1375\u201387.","journal-title":"Cancer Res"},{"issue":"4","key":"2230_CR51","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1210\/endrev\/bnae008","volume":"45","author":"J Lockett","year":"2024","unstructured":"Lockett J, Inder WJ, Clifton VL. The glucocorticoid receptor: Isoforms, Functions, and contribution to glucocorticoid sensitivity. Endocr Rev. 2024;45(4):593\u2013624.","journal-title":"Endocr Rev"},{"issue":"21","key":"2230_CR52","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1038\/onc.2010.629","volume":"30","author":"D Sidler","year":"2011","unstructured":"Sidler D, Renzulli P, Schnoz C, Berger B, Schneider-Jakob S, Fl\u00fcck C, Inderbitzin D, Corazza N, Candinas D, Brunner T. Colon cancer cells produce immunoregulatory glucocorticoids. Oncogene. 2011;30(21):2411\u20139.","journal-title":"Oncogene"},{"key":"2230_CR53","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1146\/annurev-immunol-042718-041522","volume":"37","author":"DR Simeonov","year":"2019","unstructured":"Simeonov DR, Marson A. CRISPR-Based tools in immunity. Annu Rev Immunol. 2019;37:571\u201397.","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"2230_CR54","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7150\/thno.14315","volume":"6","author":"R Liu","year":"2016","unstructured":"Liu R, Shi P, Nie Z, Liang H, Zhou Z, Chen W, Chen H, Dong C, Yang R, Liu S, Chen C. Mifepristone suppresses basal Triple-Negative breast cancer stem cells by Down-regulating KLF5 expression. Theranostics. 2016;6(4):533\u201344.","journal-title":"Theranostics"},{"key":"2230_CR55","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ejmech.2018.01.056","volume":"146","author":"Y Lin","year":"2018","unstructured":"Lin Y, Liu R, Zhao P, Ye J, Zheng Z, Huang J, Zhang Y, Gao Y, Chen H, Liu S, Zhou J, Chen C, Chen H. Discovery of novel mifepristone derivatives via suppressing KLF5 expression for the treatment of triple-negative breast cancer. Eur J Med Chem. 2018;146:354\u201367.","journal-title":"Eur J Med Chem"},{"key":"2230_CR56","doi-asserted-by":"publisher","unstructured":"Cree IA, Booton R, Cane P, Gosney J, Ibrahim M, Kerr K, Lal R, Lewanski C, Navani N, Nicholson AG, Nicolson M, Summers Y. PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. Histopathology. 2016;69(2):177\u2009\u2013\u200986. https:\/\/doi.org\/10.1111\/his.12996.","DOI":"10.1111\/his.12996"},{"key":"2230_CR57","doi-asserted-by":"publisher","first-page":"668612","DOI":"10.3389\/fmed.2021.668612","volume":"8","author":"E Tejerina","year":"2021","unstructured":"Tejerina E, Garca Tobar L, Echeveste JI, de Andrea CE, Vigliar E, Lozano MD. PD-L1 in cytological samples: a review and a practical approach. Front Med (Lausanne). 2021;8:668612.","journal-title":"Front Med (Lausanne)"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02230-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02230-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02230-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T13:03:29Z","timestamp":1771851809000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02230-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2230"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02230-x","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research protocol was reviewed and approved by the Medical Ethics Committee of The Third Affiliated Hospital of Chongqing Medical University (No. 2023\u2009\u2212\u2009100). All the animal experiments were conducted according to the protocol approved by the Animal Experimental Research Ethics Committee of Chongqing Medicine University (No. IACUC-CQMU-2022\u20130019).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}